- Epigallocatechin-3-gallate Suppresses Galactose-alpha1,4-galactose-beta1,4-glucose Ceramide Expression in TNF-alpha Stimulated Human Intestinal Epithelial Cells Through Inhibition of MAPKs and NF-kappa B
-
Moon DO, Choi SR, Lee CM, Kim GY, Lee HJ, Park YM
- KMID: 1712731
- J Korean Med Sci.
- 2005 Aug;20(4):548-554.
- doi: 10.3346/jkms.2005.20.4.548
Intestinal epithelial cells (IECs) have been known to produce galactose-alpha1,4-galactose-beta1,4-glucose ceramide (Gb3) that play an important role in the mucosal immune response. The regulation of Gb3 is important to prevent... -
- CITED
-
- Close
- SHARE
-
- Close
- The immune-stimulating peptide WKYMVm has therapeutic effects against ulcerative colitis
-
Kim SD, Kwon S, Lee SK, Kook M, Lee HY, Song KD, Lee HK, Baek SH, Park CB, Bae YS
- KMID: 2154259
- Exp Mol Med.
- 2013 Sep;45(9):e40.
In this study, we examined the therapeutic effects of an immune-stimulating peptide, WKYMVm, in ulcerative colitis. The administration of WKYMVm to dextran sodium sulfate (DSS)-treated mice reversed decreases in body... -
- CITED
-
- Close
- SHARE
-
- Close
- Malakoplakia in a healthy young female patient
-
Hyun KH, Shin HD, Kim DH
- KMID: 1503785
- Korean J Intern Med.
- 2013 Jul;28(4):475-480.
- doi: 10.3904/kjim.2013.28.4.475
Malakoplakia is a rare granulomatous disease that occurs commonly in the urinary tract and secondarily in the gastrointestinal tract. Most reported cases of malakoplakia are associated with immunosuppressive diseases or... -
- CITED
-
- Close
- SHARE
-
- Close
- Does Polyethylene Glycol (PEG) Plus Ascorbic Acid Induce More Mucosal Injuries than Split-Dose 4-L PEG during Bowel Preparation?
-
Kim MS, Park J, Park JH, Kim HJ, Jang HJ, Joo HR, Kim JY, Choi JH, Heo NY, Park SH, Kim TO, Yang SY
- KMID: 2363968
- Gut Liver.
- 2016 Mar;10(2):237-243.
- doi: 10.5009/gnl14439
BACKGROUND/AIMS: The aims of this study were to compare the bowel-cleansing efficacy, patient affinity for the preparation solution, and mucosal injury between a split dose of poly-ethylene glycol (SD-PEG) and... -
- CITED
-
- Close
- SHARE
-
- Close
- Inflammatory Bowel Disease: Updates on Molecular Targets for Biologics
-
Katsanos K, Papadakis
- KMID: 2412224
- Gut Liver.
- 2017 Jul;11(4):455-463.
- doi: 10.5009/gnl16308
Therapy for inflammatory bowel disease (IBD) has changed, with several new agents being evaluated. The era of anti-tumor necrosis factor (anti-TNF) antibody therapy saw remarkable progress in IBD therapy. Some... -
- CITED
-
- Close
- SHARE
-
- Close
